照护现场血糖监测市场规模、份额及成长分析（按类型、应用、最终用户和地区划分）－2026-2033年产业预测

预计到 2024 年，照护现场血糖监测市场规模将达到 35.8 亿美元，到 2025 年将达到 37.4 亿美元，到 2033 年将达到 51.9 亿美元，预测期（2026-2033 年）的复合年增长率为 4.2%。

由于糖尿病发病率不断上升以及定期血糖监测的重要性日益凸显，照护现场血糖监测市场正经历显着增长。携带式监测设备可提供即时结果，使医护人员和患者都能在护理现场便捷地管理血糖值。其主要优点包括：能够及时获取资讯以製定合适的治疗方案、改善患者预后以及降低整体成本。然而，设备精度、干扰因素和高成本等挑战可能会限制部分使用者的使用。生物感测器技术的创新及其与数位健康平台的融合为市场拓展提供了机会。最终，该领域的目标是帮助人们有效管理糖尿病，从而改善全球的健康状况和疾病管理策略。

照护现场血糖监测市场驱动因素

全球糖尿病盛行率的不断上升是推动照护现场血糖监测市场成长的主要因素。随着越来越多的糖尿病患者被确诊，持续血糖监测已成为有效疾病管理的迫切需求。由于越来越多的人需要定期检测以维持健康，对就地检验设备的需求持续成长。这种变化凸显了便捷高效的监测解决方案的重要性，推动了市场创新和扩张，医疗保健系统也致力于改善这种慢性疾病患者的治疗效果。

限制照护现场血糖监测市场的因素

照护现场血糖监测设备及其耗材的高成本是市场扩张的一大障碍。在医疗资源匮乏、可支配所得普遍较低的发展中地区，此价格问题尤其突出。因此，这些检测设备的高价可能会阻碍其广泛应用，尤其是在低收入者和预算紧张的医疗机构中。这种限制可能会降低照护现场血糖检测的可及性和使用率，最终影响整个市场的成长。

照护现场血糖监测市场趋势

照护现场血糖监测市场正呈现出一个显着的趋势，即把测量设备与数位健康平台和电子健康记录（EHR）系统整合起来。这种整合方式实现了无缝资料传输和即时血糖值监测，从而提高了患者参与糖尿病管理的动机。患者可以更有效地追踪血糖值，而医疗专业人员则可以获得全面的数据，以便做出更明智的治疗决策。这种技术与医疗的协同作用不仅提高了糖尿病整体诊疗的效率，还有助于个人化医疗的发展，最终改善患者的健康状况，并促进积极主动的糖尿病管理。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球照护现场血糖监测市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 采血笔和试纸
• 血糖仪

全球照护现场（按应用领域划分）及复合年增长率（2026-2033 年）

• 1型糖尿病
• 2型糖尿病

全球照护现场血糖监测市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 居家医疗环境
• 其他的

全球照护现场血糖监测市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Abbott Laboratories（USA）
• Roche Holding AG（Switzerland）
• Ascensia Diabetes Care Holdings AG（Switzerland）
• Dexcom, Inc.（USA）
• Medtronic plc（Ireland）
• LifeScan, Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• ACON Laboratories, Inc.（USA）
• Nova Biomedical Corporation（USA）
• ARKRAY, Inc.（Japan）
• Trividia Health, Inc.（USA）
• PTS Diagnostics（USA）
• Nipro Corporation（Japan）
• Ypsomed Holding AG（Switzerland）
• Sanofi SA（France）
• EKF Diagnostics Holdings plc（UK）
• Prodigy Diabetes Care, LLC（USA）
• Bayer AG（Germany）
• Danaher Corporation（USA）
• Platinum Equity Advisors, LLC（USA）

结论与建议

Point-of-care Glucose Testing Market size was valued at USD 3.58 Billion in 2024 and is poised to grow from USD 3.74 Billion in 2025 to USD 5.19 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

The point-of-care glucose testing market is experiencing substantial growth, driven by the rising incidence of diabetes and the critical need for regular glucose monitoring. Portable testing devices enable immediate results, allowing both healthcare professionals and patients to conveniently monitor blood glucose levels at the point of care. Key benefits include timely insights for informed treatment decisions, improved patient outcomes, and overall cost reduction. However, challenges such as device accuracy, interferences, and high costs may limit accessibility for some users. Innovations in biosensor technology and integration with digital health platforms present opportunities for market expansion. Ultimately, this sector aims to empower individuals to manage diabetes effectively, enhancing global health outcomes and disease management strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Point-of-care Glucose Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Point-of-care Glucose Testing Market Segments Analysis

Global Point-Of-Care Glucose Testing Market is segmented by type, application, end user and region. Based on type, the market is segmented into lancing devices and strips and blood-glucose meter. Based on application, the market is segmented into type-1 diabetes and type-2 diabetes. Based on end user, the market is segmented into hospitals and clinics, home care settings and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Point-of-care Glucose Testing Market

A significant catalyst for the growth of the point-of-care glucose testing market is the rising prevalence of diabetes worldwide. The escalating number of individuals diagnosed with diabetes creates a pressing need for consistent glucose monitoring to manage the condition effectively. As more people require regular testing to maintain their health, the demand for point-of-care testing devices continues to increase. This shifting landscape emphasizes the importance of accessible and efficient monitoring solutions, driving innovation and expansion within the market as healthcare systems strive to improve outcomes for those affected by this chronic illness.

Restraints in the Point-of-care Glucose Testing Market

The high cost associated with point-of-care glucose testing devices and their consumables poses a significant barrier to the expansion of the market. This affordability issue is particularly pronounced in developing regions where healthcare resources are scarce and disposable incomes are generally lower. As a result, the elevated prices of these testing devices can impede their broader acceptance, especially among low-income populations and healthcare institutions operating within tight budgetary limits. Consequently, this limitation can restrict the accessibility and utilization of point-of-care glucose testing, ultimately affecting overall market growth.

Market Trends of the Point-of-care Glucose Testing Market

The Point-of-care Glucose Testing market is witnessing a notable trend toward the integration of testing devices with digital health platforms and electronic health records. This cohesive approach facilitates seamless data transfer and real-time glucose level monitoring, thereby enhancing patient engagement in diabetes management. Patients can now track their glucose levels more effectively, while healthcare professionals gain access to comprehensive data for informed treatment decisions. This synergy between technology and healthcare not only improves the overall efficiency of diabetes care but also supports personalized medicine, ultimately driving better health outcomes and fostering a proactive approach to managing diabetes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Point-Of-Care Glucose Testing Market Size by Type & CAGR (2026-2033)

• Market Overview
• Lancing Devices and Strips
• Blood-Glucose Meter

Global Point-Of-Care Glucose Testing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Type-1 Diabetes
• Type-2 Diabetes

Global Point-Of-Care Glucose Testing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Home Care Settings
• Others

Global Point-Of-Care Glucose Testing Market Size & CAGR (2026-2033)

• North America (Type, Application, End User)
  • US
  • Canada
• Europe (Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascensia Diabetes Care Holdings AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LifeScan, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACON Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ARKRAY, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trividia Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTS Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nipro Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EKF Diagnostics Holdings plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prodigy Diabetes Care, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Platinum Equity Advisors, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations